Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | HTR7 | P34969 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 9/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363841 | 1.00 | HTR1A (0.43) | HTR1AHTR7DRD2ADRA1DADRA1A | |
| SCHEMBL5360944 | 0.91 | POLB (0.40) | DRD2ADRA1DADRA1AADRA1BHTR2A | |
| SCHEMBL5446985 | 0.91 | POLB (0.42) | DRD2ADRA1DADRA1AADRA1BHTR2A | |
| SCHEMBL5359455 | 0.91 | ALDH1A1 (0.45) | DRD2HTR2ADRD3POLB | |
| SCHEMBL5359450 | 0.91 | ALDH1A1 (0.45) | DRD2HTR2ADRD3POLB | |
| SCHEMBL5363070 | 0.91 | ALDH1A1 (0.45) | DRD2HTR2ADRD3POLB | |
| SCHEMBL5360942 | 0.91 | POLB (0.40) | DRD2ADRA1DADRA1AADRA1BHTR2A | |
| SCHEMBL5446988 | 0.91 | POLB (0.42) | DRD2ADRA1DADRA1AADRA1BHTR2A | |
| SCHEMBL5362995 | 0.90 | HTR1A (0.41) | HTR1AHTR7DRD2ADRA1DADRA1A | |
| SCHEMBL5362991 | 0.90 | HTR1A (0.41) | HTR1AHTR7DRD2ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282592-B2 | Resorcinol derivatives | WARNER-LAMBERT COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070122367-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7173052-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | BRADLEY STUART E | 2005-12-22 | — | — | US | disclosed |
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122367-A1 | RESORCINOL DERIVATIVES | LRAT, NQO1, ALDH1A2 | HTR1A 3210/4885HTR7 4318/4885DRD2 426/4885 |
| US-20030180236-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | HTR1A 3210/4885HTR7 4318/4885DRD2 426/4885 |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | RBP4, NQO1, ALDH1A2 | HTR1A 3659/4885HTR7 4226/4885DRD2 328/4885 |
| US-20020114770-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | HTR1A 3210/4885HTR7 4318/4885DRD2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.